Wedmont Private Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.23M Sell
32,598
-179
-0.5% -$23.6K 0.12% 102
2026
Q1
$4.64M Buy
32,777
+14,929
+84% +$2.09M 0.15% 80
2025
Q4
$2.22M Sell
17,848
-27
-0.2% -$3.28K 0.08% 147
2025
Q3
$2.09M Buy
17,875
+541
+3% +$61.5K 0.08% 155
2025
Q2
$1.96M Buy
17,334
+1,075
+7% +$114K 0.08% 147
2025
Q1
$1.68M Buy
16,259
+2,778
+21% +$287K 0.09% 141
2024
Q4
$1.21M Buy
13,481
+3,931
+41% +$354K 0.06% 185
2024
Q3
$806K Buy
9,550
+1,998
+26% +$152K 0.05% 248
2024
Q2
$528K Sell
7,552
-1,916
-20% -$128K 0.03% 327
2024
Q1
$662K Sell
9,468
-2,008
-17% -$154K 0.05% 271
2023
Q4
$964K Buy
11,476
+2,333
+26% +$182K 0.08% 169
2023
Q3
$686K Sell
9,143
-1,600
-15% -$123K 0.07% 197
2023
Q2
$829K Buy
10,743
+530
+5% +$42.3K 0.09% 152
2023
Q1
$844K Sell
10,213
-1,339
-12% -$111K 0.11% 132
2022
Q4
$1.02M Buy
11,552
+1,639
+17% +$130K 0.15% 101
2022
Q3
$612K Buy
9,913
+3,976
+67% +$251K 0.12% 132
2022
Q2
$367K Buy
+5,937
New +$368K 0.08% 190
2022
Q1
Sell
-3,083
Closed -$222K 325
2021
Q4
$222K Buy
+3,083
New +$212K 0.07% 214

Other funds holding GILD

Wedmont Private Capital's GILD Position: Q2 2026 in Review

Wedmont Private Capital reduced its Gilead Sciences (GILD) stake by 0.55% in Q2 2026, selling an estimated $23.6K and leaving 32,598 shares worth $4.23M. The position accounts for 0.12% of the portfolio, ranked #102.

Wedmont Private Capital first reported a position in GILD in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.64M in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Wedmont Private Capital held 32,598 shares of Gilead Sciences worth $4.23M as of Q2 2026.
  • Wedmont Private Capital sold 179 Gilead Sciences shares in Q2 2026, an estimated $23.6K.
  • Gilead Sciences made up 0.12% of Wedmont Private Capital's portfolio in Q2 2026, its #102 holding.
  • Wedmont Private Capital first reported a position in Gilead Sciences in Q4 2021 and has held it in 18 quarters since.
  • Wedmont Private Capital's Gilead Sciences position peaked at $4.64M in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.